In a win for Neurocrine, the Patent Trial and Appeal Board has decided to review Spruce’s endocrine patents after the USPTO director intervened.
A US biotech has failed in its bid to secure $950m in damages from an Indian generic drug maker in a dispute over COVID-19 vaccine technology.
Two new partners, who have been appointed at the Canadian law firm’s Toronto office, bring ‘extensive’ track records of success in complex patent litigation.
The final award denies all claims levied at the company in a dispute involving antibody drug technology.
Recent clashes over patents covering modified guide RNAs have exposed different approaches from the US and Europe—and new complications for the field, says Claire Irvine of HGF.
Emcure fends off COVID-19 trade secrets suit in Washington | A US biotech had inked a short-lived deal with Indian generic pharma company’s subsidiary.